2008 Supplement

MORTALITY IN RHEUMATIC DISEASES

Clinical and Experimental Rheumatology

Guest editors
T. Sokka, T. Pincus

Sponsored by the
NYU Post-Graduate Medical School

Supported by educational grants from:
Abbott Laboratories; Amgen & Wyeth Pharmaceuticals;
Bristol-Myers Squibb, Inc.; Centocor, Inc.; Genentech/Biogen IDEC; Pfizer, Inc.

Release date: December 15, 2008
Expiration date: December 14, 2009
Target Audience
This activity is designed for rheumatologists.

Statement of Need
Mortality in Rheumatic Diseases is a much-neglected area, which could give an improved visibility to these diseases and sense of urgency concerning treatment, as well as support for further research for rheumatic diseases. In many patients, diseases such as vasculitis, scleroderma, systemic lupus erythematosus, polymyositis, etc. have a natural history disease that includes as severe a risk of early death as most forms of cancer and cardiovascular disease. However, rheumatic diseases are not associated with a similar aura of severity as neoplastic and malignant diseases. Rheumatologists, rheumatology fellows, internists and family practitioners need to understand the severity of rheumatic diseases by promoting knowledge of increased risk of premature death.

Educational Objectives
- describe the mortality risks posed by many rheumatic diseases, specifically, ankylosing spondylitis, scleroderma, systemic lupus erythematosus, and vasculitis.
- discuss effective treatments for rheumatic diseases and the importance of early and effective intervention.

Accreditation Statement
The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The NYU Post-Graduate Medical School designates this educational activity for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should only claim credits commensurate with the extent of their participation in the activity.

Method of Participation
To receive up to 9.0 CME credits, read this supplement, which should take 9.0 hours of your time, complete the post-test with a minimum passing grade of 70%, complete the evaluation, and submit to the NYU Post-Graduate Medical School (instructions enclosed).

This activity is valid for credit from December 15, 2008 through December 14, 2009.

Faculty Credentials

Stefano Bombardieri, MD
Professor of Rheumatology
Rheumatic Disease Unit
Department of Internal Medicine
University of Pisa
Pisa, Italy

Jürgen Braun, MD
Professor of Medicine and Rheumatology
Rheumazentrum-Ruhrgebiet
St.Josefs-Krankenhaus
Herne, Germany

Hyon K. Choi, MD, DrPH
Professor of Rheumatology
Division of Rheumatology
Department of Medicine
University of British Columbia
Arthritis Research Centre of Canada
Vancouver, BC, Canada

Dafna D. Gladman, MD, FRCP
Professor of Medicine, University of Toronto
Senior Scientist, Toronto Western Research Institute
Deputy Director, Centre for Prognosis Studies in The Rheumatic Diseases
Director, Psoriatic Arthritis Program
Toronto, ON, Canada

Marc C. Hochberg, MD, MPH
Professor of Medicine and Epidemiology and Preventive Medicine
Head, Division of Rheumatology and Clinical Immunology
University of Maryland School of Medicine
Baltimore, Maryland, USA

John P.A. Ioannidis, MD
Professor and Chairman, Department of Hygiene and Epidemiology
University of Ioannina School of Medicine
Ioannina, Greece
and Institute for Clinical Research and Health Policy Studies
Department of Medicine
Tufts Medical Center
Boston, MA, USA

Ingrid E. Lundberg MD, PhD
Professor, Rheumatology Unit
Department of Medicine
Karolinska University Hospital
Stockholm, Sweden

Raashid Luqmani, DM, FRCP
Senior Lecturer
Botnar Research Centre
University of Oxford
Oxford, UK

Haralampos M. Moutsopoulos, MD
Professor and Head, Department of Pathophysiology, Medical School
National University of Athens
Athens, Greece